Nicox confident of allaying FDA concerns on key eye care products

9 November 2016

French biotech Nicox (Euronext Paris: COX) is confident that – together with its partners – it can overcome the concerns of the US Food and Drug Administration (FDA) in relation to its key products, latanoprostene bunod and AC-170.

The ophthalmic research and development company has updated investors on the progress of the two eye care treatments, the prompt approval of which are key to Nicox’s development plans for other candidates.

Bausch + Lomb, a wholly-owned subsidiary of Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) and Nicox’ licensee for latanoprostene bunod, expects the launch of latanoprostene bunod to take place in mid-2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK